Back

MCLA-128 ASCO Poster (June 2017)

First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).

Maria Alsina, Valentina Boni, Aurelia de Vries Schultink, Victor Moreno, Kees Bol, Martine Westendorp, L. Andres Sirulnik, Josep Tabernero, Emiliano Calvo.